Primary Central Nervous System Lymphoma
Conditions
Brief summary
This is a single arm, single center, open label pilot study of Orelabrutinib combined with Rituximab, high-dose (HD) Methotrexate and Dexamethasone in newly-diagnosed primary central nervous system lymphpoma (PCNSL). The purpose is to evaluate the safety and to find the optimal dose of Orelabrutinib and Methotrexate in this combination treatment for newly-diagnosed PCNSL patients.
Detailed description
The eligible patients will be treated with Orelabrutinib combined with Rituximab, high-dose Methotrexate and Dexamethasone during induction treatment (6-8 cycles; 21 days/cycle): Rituximab 375 mg/m2, intravenous infusion, d1; HD-MTX 3.5 g/m2 intravenous infusion (3h), d2; Dexamethasone 10-15 mg, iv, d1-4. Orelabrutinib will be given 72h after MTX infusion or until MTX clearance. The study will investigate optimal dose combination of Orelabrutinib and MTX implementing BOIN waterfall design. The starting dose of Orelabrutinib is 150 mg/d and the dose will be escalated to 200 mg/d, throughout the whole cycle. Meanwhile, the starting dose of MTX is 3g/m2 and will be escalated to 5g/m2, throughout induction phase. Dose escalation and movement in dose matrix will be determined by BOIN algorithm. For CR/CRu patients after completion of induction treatment, daily Orelabrutinib will be administered as maintenance treatment for up to 1 year or until disease progression, intolerable toxicity, death, informed consent withdrawal or lost of follow up (whichever occurs first). Patients will be evaluated every 2 cycles during induction therapy and every 12 weeks during maintenance therapy.
Interventions
DRUGOrelabrutinib
Orelabrutinib will be given as 150 mg/d or 200 mg/d orally 72h after MTX infusion or MTX clearance, every 21 days for 6-8 cycles during combination induction treatment. Daily Orelabrutinb with dose in last cycle of induction will be administered as maintenance treatment for up to 1 year or until disease progression, intolerable toxicity, death, informed consent withdrawal or lost of follow up (whichever occurs first).
DRUGRituximab
Rituximab 375 mg/m2 intravenous infusion d1, every 21 days for 6-8 cycles during combination induction treatment.
DRUGMethotrexate (MTX)
high-dose Methotrexate 3.5 g/m2 or 5g/m2 intravenous infusion (3h) d2, every 21 days for 6-8 cycels during combination induction treatment.
DRUGDexamethasone
Dexamethasone 10-15 mg, iv, d1-4, every 21 days for 6-8 cycles during combination induction treatment.
Sponsors
Huashan Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* anti-neoplasm systemic treatement naive primary central nervous system lymphoma * Pathological type is diffuse large B cell lymphoma * Enough residual sample of tumor after pathological diagnosis * ECOG =\<3 * Life expectancy \>3 months * Adequate organ function and adequate bone marrow reserve * Must be able to tolerate lumbar puncture and/or have Omaya tube * Participant or his/her legal agent must be willing to sign a written informed consent document.
Exclusion criteria
* Lymphoma invading outside CNS * Lymphoma only existed in vitreo-retina * Severe or uncontrolled cardiovascular disease * Active hemorrhage within 2 months prior screening * Cerebral ischemic stroke or bleeding within 6 months prior screening * Organ transplantation or allogeneic hematopoietic stem cell transplantation history * Other surgery history within 6 weeks prior screening * Anti-tumor herbal medicine treatment within 4 weeks prior screening * Activated or uncontrolled hepatitis virus B infection (HBsAg positive with/or HBc Ab positive and HBV-DNA titration positive), hepatitis virus C antibody positive, HIV positive. * Uncontrolled active systemic fungal, bacterial, virus or other microbe infection, or intravenous injection of antibiotics needed * Accepted live vaccine or immunization within 4 weeks prior eligibility * Continuously taking drugs with medium / strong inhibition or induction of cytochrome P450 CYP3A is needed * Allergy to orelabrutinib or the subsidiary (or supplementary) material (Hydroxypropyl methylcellulose acetate succinate, mannitol, cross-linked sodium carboxymethylcellulose, hydroxypropyl cellulose, silica and magnesium stearate) * Obvious gastro-bowel disease which may influence the intaking, transportation or absorption of the drug, or total gastrectomy * Past or present pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, or drug-related pneumonia, with severe impairment of pulmonary function * Chronic liver damage, severe fatty liver or alcoholic liver disease * Intention to undergo autologous stem cell transplantation * Pregnant or breeding women, or women of childbearing age who are unwilling to take contraceptive measures during the whole study period and within 180 days after the last administration of the study drug; non surgically sterilized men who are unwilling to take contraceptive measures during the whole study period and within 180 days of the last administration of the study drug. * Potentially life-threatening situation, or severe organ dysfunction, or situations the researchers believe not suitable for the trial * Any mental or cognitive impairment which may limit the understanding and implementation of informed consent or the compliance with the study. * previously exposed with WBRT
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| define the Maximum tolerated dose (MTD) contour of Orelabrutinib and MTX | From the start of the first dose of Orelabrutinib to the end of the first cycle of induction treatment (21 days/cycle) | A BOIN waterfall design will be employed. Two dose levels of Orelabrutinib (dose level 1: 150 mg/d, dose level 2: 200 mg/d) and two dose levels of MTX (dose level 1: 3.5g/m2, dose level 2: 5g/m2) will be investigated, generating 4 dose combination. DLT was defined by the occurrence of severe toxicities during the first cycle: any grade 4 hematologic toxicity, grade 3 febrile neutropenia and grade 3 thrombocytopenia with hemorrhage, or any grade 3 non-hematologic toxicity that failed to respond to supportive therapy and possibly related to orelabrutinib and/or MTX (assessed according to NCI CTCAE V5.0) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| ORRi | At the end of cycle 6-8 (each cycle is 21 days) | ORRi is defined as the proportion of patients with a best response of CR, CRu or PR during induction therapy |
| CRi | At the end of cycle 6-8 (each cycle is 21 days) | CRi is defined as the proportion of patients with a best response of CR or CRu during induction treatment |
| TTR | At the end of cycle 6-8 (each cycle is 21 days) | Time to response during induction therapy |
| ORRm | At the end of completion of 1 year of maintenance treatment | ORRm is defined as the proportion of patients with a best response of CR, CRu or PR during maintenance therapy |
| CRm | At the end of completion of 1 year of maintenance treatment | CRm is defined as the proportion of patients with a best response of CR or CRu during maintenance therapy |
| Progression-free survival | Up to 2 years | Progression-free survival is calculated from the date of start of therapy until the date of first documented progress or death due to any cause. |
| Overall survival | Up to 2 years | Overall survival is defined as the duration from start of treatment to time of death. |
Countries
China
Contacts
PRINCIPAL_INVESTIGATORTong Chen
Huashan Hospital
Outcome results
None listed